Identification of the glycosaminoglycan-binding site on the glycoprotein Erns of bovine viral diarrhoea virus by site-directed mutagenesis

Munir Iqbal and John W. McCauley

Division of Molecular Biology, Institute for Animal Health, Compton Laboratory, Compton, Newbury RG20 7NN, UK

Bovine viral diarrhoea virus (BVDV) envelope glycoprotein Erns interacts with highly sulphated heparin-like glycosaminoglycans (GAGs) located on the cell surface as an early step in virus infection of cells. Site-directed mutagenesis of recombinant Erns was undertaken and analysis of mutants by heparin-affinity chromatography and cell surface binding showed that a cluster of basic amino acids (480KKLENKSK487) near the C terminus of Erns was essential for binding. Mutants with amino acid substitutions of lysine residues 481 and 485 in Erns reduced the binding of Erns to immobilized heparin and cellular GAGs but retained ribonuclease activity. In contrast to normal Erns, Erns that was unable to bind to cells also failed to inhibit BVDV infection of cells when the cells were pre-incubated with Erns. It is proposed that the cluster of basic residues (480KKLENKSK487) localized at the C-terminal end of Erns constitutes a GAG-binding site.

Introduction

Bovine viral diarrhoea virus (BVDV) is a major cattle pathogen with a worldwide distribution, which, together with classical swine fever virus (CSFV) of pigs and border disease virus (BDV) of sheep, belongs to the genus Pestivirus of the family Flaviviridae (Thiel et al., 1996). Many members of this family can cause severe human disease, such as hepatitis C virus, dengue virus and yellow fever virus (Pringle, 1998). The pestivirus genome comprises positive-stranded RNA that is translated to form a single virus polyprotein, which, through cleavage by both host and virus proteases, gives rise to 11 or 12 mature viral proteins (NH2-Npro-C-Erns-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH) (Rice, 1996). Erns, E1 and E2 are glycoproteins found on the surface of the virion. Erns lacks a typical transmembrane domain and a proportion of this protein is secreted from infected cells into the extracellular environment (Rumenapf et al., 1993) and also contains a ribonuclease activity (Hulst et al., 1994; Schneider et al., 1993; Windisch et al., 1996). The role of ribonuclease activity in the virus life cycle is not clear. It has been reported that a genetically engineered strain of CSFV, which lacks ribonuclease activity,induced cell death in swine kidney cells but the parent virus did not (Hulst et al., 1998). However, another mutant CSFV lacking ribonuclease activity was not cytopathogenic (Meyers et al., 1999). Recently we have assigned an additional function to Erns: BVDV glycoprotein Erns binds to glycosaminoglycans (GAGs) on the cell surface (Iqbal et al., 2000); subsequently, this was also shown for Erns of CSFV (Hulst et al., 2000).

Heparin is present in the form of heparan sulphate proteoglycans on the cell surface and a large number of viruses utilize heparan sulphate to mediate attachment and infection of target cells. Examples can be found within many virus families: for example, members of the families Flaviviridae (Chen et al., 1997; Hilgard & Stockert, 2000; Su et al., 2001), Herpesviridae (Terry-Allison et al., 2001) and Picornaviridae (Jackson et al., 1996); human immunodeficiency viruses (Di Caro et al., 1999), human respiratory syncytial virus (Martínez & Melero, 2000), adenovirus types 2 and 5 (Dechecchi et al., 2001); and members of the genus Alphavirus (Byrnes & Griffin, 1998). The binding of proteins and glycoproteins to GAGs is often mediated through heparin-binding domains (HBDs), which are found in a wide range of proteins and are characterized by an overall positive charge. Common structural motifs have been proposed: the sequences BBXB, XBBXB and XBBBXXBX (where B designates a basic amino acid and X designates any other residue) have been suggested to act as heparin-binding regions (Hileman et al., 1998; Sobel et al., 1992).
The amino acid sequence of E\textsuperscript{Ems} has two conserved sequences, \textsuperscript{466}KKKG\textsuperscript{469} and \textsuperscript{488}KKLENKSK\textsuperscript{487}, which closely match consensus HBD sequences. Here we examine whether these putative heparin-binding consensus sequences present in E\textsuperscript{Ems} are involved in E\textsuperscript{Ems}–GAG binding; we describe their relative affinities for heparin and cell surface binding; and the ability of mutated E\textsuperscript{Ems} to block BVDV infection.

Methods

- **Cells and viruses.** Calf testes (CTe) cells were maintained in Eagle’s minimum essential medium (EMEM) supplemented with 10% BVDV-free foetal calf serum (FCS), 5% lactalbumin hydrolysate and 0.1% penicillin G and streptomycin (100 µg/ml). Insect cells (Schneider S2; Drososphiola) were obtained from Invitrogen and grown at room temperature in DES expression medium (Invitrogen) containing 10% FCS. Working stock (passage no. 12) of BVDV cytopathogenic (CP) virus strain Pe515 (Pocock et al., 1987) was prepared in CTe cells.

- **Site-directed mutagenesis of heparin-binding sites.** The E\textsuperscript{Ems} gene was cloned previously into a Drosophila expression vector to produce pMT/BIP/E\textsuperscript{Ems}/V5-His, which represented the full-length E\textsuperscript{Ems} cDNA of BVDV (non CP) strain Pe515 corresponding to amino acids 268–494 of the BVDV polyprotein (Iqbal et al., 2000). Specific mutation of positively charged amino acids in putative heparin-binding motifs of E\textsuperscript{Ems} was carried out to substitute lysine for uncharged amino acids (alanine, glycine or threonine). Mutagenesis was done by PCR using the Quick Change Site-Directed Mutagenesis kit (Stratagene) following the manufacturer’s guidelines. The sequences of the mutagenic primers used for the constructs can be obtained from the authors upon request. Sequencing of mutated plasmids was carried out commercially (MWG-Biotech). A deletion mutant of E\textsuperscript{Ems} (A480–494 E\textsuperscript{Ems}), where the C-terminal 15 amino acids of mature E\textsuperscript{Ems} were deleted, was constructed by PCR and cloned into the DES expression vector pMT/BIP/V5-His (Invitrogen). The primers used were: 5‘ ATTCAAGTTACAAGTCTGAAATATAAACA 3’ (sense orientation), which corresponds to nucleotides 1178–1207 of the BVDV genome sequence modified to include a BglII recognition site (bold letters) on the 5′ end of the E\textsuperscript{Ems} sequence; and 5‘ CTGTTTCTCATACTGACTGATATCC 3’ (anti-sense orientation), which corresponds to nucleotides 1820–1849 of the BVDV genome sequence modified by the inclusion of an XbaI recognition site (bold letters). Plasmids (pMT/BIP/E\textsuperscript{Ems}/V5-His) containing the genes encoding wild-type, mutated or deleted E\textsuperscript{Ems} were individually cotransfected with a hygromycin-resistant selection vector pCoHYGRO (Invitrogen) at a ratio of 19 (pMT/BIP/E\textsuperscript{Ems}/V5-His) to 1 (pCoHYGRO) into insect (S2) cells using a Calcium Phosphate Transfection kit (Invitrogen), according to the supplier’s instructions.

- **Expression and purification of wild-type and mutant E\textsuperscript{Ems}.** Wild-type and mutant E\textsuperscript{Ems} glycoproteins were expressed and purified as described previously (Iqbal et al., 2000). Briefly, Drosophila S2 cells harbouring the E\textsuperscript{Ems} gene were grown in Ultrade Insect serum-free medium (Invitrogen) and expression of V5-tagged E\textsuperscript{Ems} (E\textsuperscript{Ems}V5) was induced by the addition of 5 mM copper sulphate. The culture supernatants collected 72 h post-induction were dialysed against equilibration buffer (20 mM Tris–HCl, pH 7.8, and 500 mM NaCl) and subjected to nickel affinity chromatography (Probound, Invitrogen). The column was washed with 20 mM Tris–HCl, pH 6.0, containing 1.0 M NaCl and 50 mM imidazole and E\textsuperscript{Ems} was eluted with 20 mM Tris–HCl, pH 6.0, containing 300 mM imidazole. Fractions containing E\textsuperscript{Ems}V5 were pooled and the concentration of protein was determined using the Coomassie reagent (Pierce).

- **Binding of E\textsuperscript{Ems} and its mutants to heparin.** The relative affinity of wild-type and mutant E\textsuperscript{Ems} to immobilized heparin was determined by loading the S2 cell culture supernatants containing wild-type or mutant proteins onto a 1 ml heparin–agarose column (Sigma) equilibrated previously with 20 mM Tris–HCl, pH 7.8. The column was washed with equilibration buffer and eluted in 1 ml fractions with a stepwise gradient of increasing concentrations of NaCl (0–1–0 M) in equilibration buffer. Dilutions of each fraction were coated onto a 96-well ELISA plate at 4 °C overnight and then blocked with 5% skimmed milk in PBS. E\textsuperscript{Ems} was detected using an anti-V5 antibody (a generous gift from Professor R. Randall, University of St. Andrews, Scotland, UK).

- **Cell surface binding assay.** Confluent cell monolayers of CTe cells in 96-well plates were washed twice with PBS, fixed with 4% paraformaldehyde in PBS for 45 min at room temperature and blocked overnight at 4 °C with blocking buffer (5% normal goat serum and 0.01% Na\textsubscript{3}PO\textsubscript{4} in PBS). The cells were then incubated with 0.3 µg wild-type or mutant E\textsuperscript{Ems} in PBS in a total volume of 50 µl for 1 h at room temperature. Subsequently, the cells were washed three times with PBS. Bound wild-type and mutant E\textsuperscript{Ems} were detected with an anti-E\textsuperscript{Ems} monoclonal antibody (WB210, Veterinary Laboratories Agency) or an anti-V5 monoclonal antibody (ibid).

- **Inhibition of BVDV infection of cells by E\textsuperscript{Ems}.** Confluent monolayers of CTe cells growing in 6-well plates were rinsed twice with serum-free EMEM and pre-incubated with 500 µl serum-free EMEM containing recombinant wild-type E\textsuperscript{Ems}, mutant E\textsuperscript{Ems} or control protein at 37 °C. After 1 h, dilutions of 500 µl CP BVDV (75 p.f.u.) in serum-free EMEM were added to the wells. When the virus solution was added, the concentration of protein (wild-type E\textsuperscript{Ems} mutant E\textsuperscript{Ems} or GFP/V5) was diluted to 20 µg/ml (the concentration at which inhibition was measured). The virus–protein mixture was further allowed to adsorb for 1 h at 37 °C, after which the cells were washed three times with EMEM and overlaid with maintenance medium containing 1% agarose. The cells were then incubated at 37 °C for 3 days. The cells were stained with toluidine blue (0.1% toluidine blue and 4% formaldehyde in PBS) and the number of CP virus plaques was counted.

- **Ribonuclease activity of E\textsuperscript{Ems}.** Ribonuclease activity of wild-type and mutant E\textsuperscript{Ems} was carried out essentially as described by Hulst et al. (1994). Briefly, the assay mixture (25 µl in total) contained 0.2 µg purified wild-type or mutant E\textsuperscript{Ems} and 12.5 µg of yeast 16–23S RNA in 20 mM sodium acetate buffer, pH 4.5. The mixture was incubated at 37 °C for varying time-points (5–45 min) and the enzyme reaction was stopped by acid precipitation using 5 µl of 25% (v/v) HClO\textsubscript{4} containing 0.75% (w/v) uranyl acetate. After cooling on ice for 10 min, the reaction mixture was centrifuged for 5 min at 10000 g and the absorbance at 260 nm of the supernatant was measured. The specific ribonuclease activity was expressed as A\textsubscript{260} units per min per mg of E\textsuperscript{Ems}.

Results

**Construction of E\textsuperscript{Ems} mutants.**

The BVDV glycoprotein contains two clusters of basic amino acids: \textsuperscript{466}KKKG\textsuperscript{469} (HBD-1), which exactly matches various viral and mammalian heparin-binding site sequences (Feldman et al., 1999; Hileman et al., 1998; Proudfoot et al., 2001), and \textsuperscript{488}KKLENKSK\textsuperscript{487} (HBD-2) in the polyprotein of...
BVDV strain Pe515, both may be potential heparin-binding sites. Both of these regions of basic amino acids are conserved among all the BVDV strains for which data have been deposited in sequence databases. To determine whether the basic amino acid residues in these potential heparin-binding motifs are indeed responsible for \( \text{E}^{\text{rns}} \)-GAG-binding activity, a series of single and double mutants, generated by site-directed mutagenesis by substituting lysine with neutral residues, and a single deletion mutant (a deletion of 15 amino acids, 480–494) were made. A total of 11 single, double and deletion mutants was constructed (Fig. 1).

**Effect of \( \text{E}^{\text{rns}} \) mutation on heparin-binding affinity**

The relative affinities of the recombinant proteins for heparin were assessed by chromatography on heparin–agarose columns. Wild-type and mutant \( \text{E}^{\text{rns}} \) proteins were expressed in *Drosophila* S2 cells and culture supernatants were applied to heparin–agarose columns and eluted with a stepwise gradient of an increasing concentration of NaCl (0–1–1 M). Wild-type and \( \text{E}^{\text{rns}} \) mutants, K406A–K407T, K406A, K407T and K409G, in which basic amino acids had been substituted in the first potential HBD, HBD-1, and two mutants, K406A and K487G, from the second potential HBD, HBD-2, eluted between 0.5 and 1 M NaCl. These results indicated that the heparin-binding affinity of these \( \text{E}^{\text{rns}} \) mutants was like wild-type \( \text{E}^{\text{rns}} \) (Fig. 2a). In contrast, the other mutants from HBD-2, K480A–K481T, K485A–K487G, K481T and K485A and the deletion mutant A480–494 eluted from the matrix at 0.2–0.4 M NaCl (Fig. 2b) and showed reduced heparin binding. From these results we deduce that two basic residues of \( \text{E}^{\text{rns}} \), Lys481 and Lys485, are critical for binding to the heparin matrix.

**\( \text{E}^{\text{rns}} \) mutants that lack heparin-binding ability retain their RNase activity**

To ensure that the changes introduced into \( \text{E}^{\text{rns}} \) did not induce extensive conformational change to the molecule, the ribonuclease activity of \( \text{E}^{\text{rns}} \) was examined. The specific ribonuclease activities of the purified wild-type and \( \text{E}^{\text{rns}} \) mutants K480A–K481T, K485A–K487G, K481T and K485A and the deletion mutant A480–494 were: 756, 822, 634, 712, 568 and 613 A_{260} units per min per mg, respectively. These results demonstrated that mutant \( \text{E}^{\text{rns}} \) showed no significant loss of ribonuclease activity.

**Effect of \( \text{E}^{\text{rns}} \) mutations on binding to the cell surface**

The \( \text{E}^{\text{rns}} \) mutants were examined for their differences in cell surface binding. Purified recombinant proteins were incubated with paraformaldehyde-fixed CTe cells and the relative binding of mutant proteins was analysed by ELISA. The data, shown in Fig. 3, demonstrated that wild-type and six mutants of glycoprotein \( \text{E}^{\text{rns}} \) (K406A–K407T, K406A, K407T, K409G, K480A and K487G) showed similar binding to CTe cells but mutants K480A–K481T, K485A–K487G, K481T and K485A and the deletion mutant A480–494 had lost their ability to bind to the surface of cells. These results show that residues Lys481 and Lys485 are important residues involved in binding to cell surface GAGs. Notably, the ability of \( \text{E}^{\text{rns}} \) to bind to cells correlates with their affinity for immobilized heparin.
Fig. 3. Binding profiles of E<sup>rns</sup> mutants to CTe cells. Cell surface binding of wild-type and mutant E<sup>rns</sup> was measured by incubation of E<sup>rns</sup> with paraformaldehyde-fixed CTe cells in 96-well plates for 1 h at room temperature. E<sup>rns</sup> bound to cells were detected by ELISA using an anti-V5 monoclonal antibody. Each bar represents the mean of at least two independent experiments and error bars show the standard deviations from triplicate data points.

Fig. 4. Effect of amino acid substitutions in the E<sup>rns</sup> protein on its ability to inhibit BVDV infection. E<sup>rns</sup> mutants were tested for their ability to block virus infection by treating the CTe cells with wild-type E<sup>rns</sup>; mutant E<sup>rns</sup> or GFP/V5 (control) for 1 h at 37 °C. Cells were then inoculated with approximately 75 p.f.u. of CP BVDV. The final concentration of E<sup>rns</sup> mutant E<sup>rns</sup> or GFP/V5 was diluted to 20 µg/ml and incubated for a further 1 h. The cells were then washed and overlaid with medium containing 1% agarose. After incubation for 3 days, the cells were fixed and stained and the plaques counted. Error bars show the standard deviations from triplicate data points.

Ability of mutant E<sup>rns</sup> to block virus infectivity

To determine whether the observed impairment of E<sup>rns</sup> mutants in cell surface binding and binding to immobilized heparin also correlated with inhibition of virus infection, CTe cells were incubated with wild-type and mutant proteins and subsequently infected with CP BVDV virus. As shown in Fig. 4, the addition of wild-type E<sup>rns</sup> and mutant E<sup>rns</sup>, K<sup>406</sup>A–K<sup>497</sup>T, K<sup>406</sup>A, K<sup>407</sup>T, K<sup>409</sup>G, K<sup>408</sup>A and K<sup>487</sup>G during the period of virus attachment reduced plaque formation. In contrast, E<sup>rns</sup> mutants K<sup>406</sup>A–K<sup>483</sup>T, K<sup>483</sup>A–K<sup>497</sup>G, K<sup>481</sup>T and K<sup>483</sup>A and the deletion mutant Δ480–494 showed no significant inhibitory effect on virus infection compared to the GFP/V5 negative control protein. Hence, we conclude that E<sup>rns</sup> mutants with lysine residues at positions 481 and 485 changed to neutral amino acid residues were defective in heparin and cell surface binding and also lost their ability to block virus infection.

Discussion

Recently we showed that BVDV glycoprotein E<sup>rns</sup> binds to immobilized heparin and interacts with cell surface heparan sulphate-like GAGs and proposed that BVDV interacts initially with the infected cell through this mechanism (Iqbal et al., 2000). In this report, we localized a functional site on E<sup>rns</sup> that is involved in binding to cell surface GAGs and we determined the relative importance of positively charged residues in two potential HBDs (K<sup>480</sup>KKGK<sup>489</sup> and K<sup>480</sup>KKLENKSK<sup>487</sup>) of E<sup>rns</sup>. The results from site-directed mutagenesis of E<sup>rns</sup> presented here indicated that binding of the E<sup>rns</sup> to GAGs involves lysine residues at positions 481 and 485 of the virus polypeptide, the motif at residues 406–409 had no effect on GAG binding.

In CSFV, strain Brescia, Hulst et al. (2000) observed that the affinity of the virus for heparin increased after passage in tissue culture. These authors showed that residue 476 was involved in determining the affinity of the virus for heparin, since, on adaptation to tissue culture, this residue changed from Ser to Arg; this residue is adjacent to the heparin-binding motif that we have identified here for BVDV. At position 476, strains of CSFV vary with lysine, arginine or serine residues present but all BVDV and BDV sequences deposited in sequence databases are distinct and have glycine at that position. (In this study, we have not examined the effect of changing the conserved glycine at position 476 of BVDV E<sup>rns</sup>.) Like residue 476, the region we have identified (K<sup>480</sup>KKLENK<sup>487</sup>) as a GAG-binding site is totally conserved in all BVDV strains sequenced to date. As a comparison with the examples from sequence databases, we have examined the amino acid sequence of this region of BVDV E<sup>rns</sup> directly from the serum of three persistently infected calves. RT–PCR and sequencing the cDNA products prepared from serum samples showed a conserved amino acid sequence between residues 470 and the C terminus of E<sup>rns</sup> in the region of the GAG-binding motif we have identified (data not shown). We submit, therefore, that adaptation of BVDV to tissue culture does not select for mutations around the GAG-binding motif and changes in binding to GAGs; this contrasts with observations made on CSFV (Hulst et al., 2000). This GAG-binding motif is also highly conserved in BDV isolates; the only variation has been observed is residue 485. In BDV, residue 485 may be asparagine (as observed in BVDV) or histidine, which makes the BDV consensus KKLEN<sub>N</sub>/<sub>H</sub>K. This region is somewhat different in CSFV isolates. The sequence
reported most frequently in this region for CSFV isolates is KRLEGR but the consensus sequence can be described as $K/R^{\alpha}K^{\beta}s/K^{\alpha}/R^{\alpha}$. Notably, in all pestiviruses the LE motif is totally conserved. The significance of the change between CSFV and the BVDV/BDV group is unclear but it may correlate with the fine specificity of GAG binding and the important influence of residue 476 in CSFV.

The GAG-binding motif for all pestiviruses can be summarized as BBLEXSB. This sequence does not exactly match any of the motifs for heparin binding adduced by Hileman et al. (1998). Similarly this region of Eterns does not match the other motifs: the XBBBXXB motif, typified by IL8, or the TXBXXTBXXXXTBB motif, typified by fibroblast growth factors.

There is a wide range of diverse interactions between cell surface proteoglycans and proteins or glycoproteins. Normal physiological interactions range from coagulation cascades, growth factor signalling and cell adhesion to lipase binding (Davies et al., 2001; Feldman et al., 2000; Hussain et al., 2000; Koyama et al., 1991; Wuppermann et al., 2001). Likewise, viruses interact with proteoglycans in a number of ways. Several viruses may use cell surface proteoglycans as a step in virus attachment to cells but other virus molecules are not involved in the binding of virus to cells. Two well-studied examples of virus particles binding to GAGs are worth considering.

The importance of binding to cell surface GAGs of members of the family Herpesviridae in virus entry has recently been reviewed (Raijani & Vojvodova, 1998). Herpes simplex virus (HSV) contains at least two glycoproteins that bind to GAGs, gB and gC, and the residues involved in binding to GAGs have been identified. In the alphaherpesviruses pseudorabies virus and bovine herpesvirus-1 the gC glycoproteins contain multiple HBDS (Flynn & Ryan, 1996; Liang et al., 1993), whereas the gC of HSV-1 appears to have a single GAG-binding region (Mårdberg et al., 2001; Tal-Singer et al., 1995; Trybala et al., 1994). Clearly, at least some herpesviruses interact with GAGs through multiple proteins in multiple interactions.

On the other hand, the crystal structure of foot-and-mouth disease virus (FMDV) associated with GAGs has revealed that there is a single site of interaction between GAGs and the virus particle. The interaction is formed by three virus capsid proteins (Fry et al., 1999) with special importance associated with arginine at position 56 of VP3. This residue in field strains is histidine but arginine is selected on passage in tissue culture, which parallels an increased affinity for heparin but attenuation for cattle (Sa-Carvalho et al., 1997). The adaptation of FMDV to tissue culture may be analogous to the adaptation of CSFV to tissue culture. There is no structural information available for pestivirus glycoproteins and whether variation in the affinity of the Eterns glycoprotein of BVDV for GAGs affects virulence is not known. For BVDV and BDV, we do not know whether there is a selective pressure in culture to increase the affinity of the virus for GAGs. However, the highly conserved nature of the GAG-binding region in both BVDV and BDV and the absence of the variant amino acids in that region observed in CSFV prompts us to suggest that adaptation of GAG binding in tissue culture is not a major issue. However, the mutation of a single region in BVDV Eterns and the alteration of the affinity for heparin in CSFV close to this site suggest that there is a single GAG-binding motif in Eterns.

The binding of cytokines and growth factors to GAGs is thought to be an important mechanism favouring a paracrine action rather than a systemic action. It is hypothesized that binding to sulphated polysaccharides may focus the action of soluble polypeptides locally. Examples include many interleukins (for example, see Mummery & Rider, 2000) and IFN-γ (Lortat-Jacob & Grimaud, 1991; Lortat-Jacob et al., 1995). Interaction with proteoglycans local to the site of infection also may be an important way for viruses to influence their local environment. This strategy seems to have been utilized by some poxviruses. Many secreted poxvirus proteins bind to GAGs; examples include a complement control protein (Smith et al., 2000) and the chemokine antagonists MC148 from Mallotus contagiosum (Damon et al., 1998) and MT-1 from myxoma virus (Seth et al., 2001). The GAG-binding activity of these virus proteins may well retain the activity of these polypeptides local to the site of virus infection acting in a paracrine fashion.

Eterns is a structural component of the virus particle but it is also secreted from infected cells. Eterns has the opportunity to act not only in virus entry but also as a paracrine mediator of an undefined activity. It is possible that an unknown function of Eterns as a secreted glycoprotein may require its GAG-binding activity. Whether such a function is required during the acute phase of infection or in establishing a persistent infection is open to investigation. Identification of the residues involved in the interaction between Eterns and glycosaminoglycan proteoglycans should promote the design of experiments to dissect the function of this glycoprotein in the natural history of pestiviruses.

Note added in proof. Langedijk (Journal of Biological Chemistry 277, 5306–5314, 2002) has recently shown that peptides corresponding to the C-terminal domain of Eterns were able to enter the cell and localize to nuclei. In his study, deletion of the region identified here as the GAG-binding motif of Eterns abrogated that activity.

We thank Dr Martin Fray and Dr Sue Baigent for discussion and for critically reviewing the manuscript.

References


saminoglycans.


Received 14 December 2001; Accepted 16 April 2002